Remdesivir
Educational summary, not a formulary. Dosing is quoted from the Makindo chapters and topics site. The other sections are draft summaries not yet checked line by line against the BNF or SPC. Check dose, indication, interactions and monitoring in the BNF entry for Remdesivir and local guidelines before prescribing.
Antiviral
Mechanism
Nucleotide analogue inhibiting viral RNA polymerase.
Uses
COVID-19 in hospitalised or high-risk patients.
Dosing
No dose is given in the chapters. See the BNF.
Side effects
Nausea, raised transaminases, infusion reactions, bradycardia.
Interactions
Few; chloroquine antagonism.
Contraindications and cautions
Hypersensitivity
Monitoring
LFT, U&E
Pregnancy and breastfeeding
Use if essential
Renal and hepatic impairment
Caution in severe renal impairment
Overdose and reversal
Supportive
Special advice
Check LFT and renal function.
More from the textbook: uses, cautions and other points
- Early antivirals for people at high risk of severe disease (within 5 days of symptoms) - nirmatrelvir–ritonavir (major interactions), sotrovimab or remdesivir (NICE).
ID: Viral, fungal and parasitic infections - Sotrovimab (neutralising antibody), remdesivir (IV, hospital use).
ID: How Infection Happens - RNA polymerase | Sofosbuvir (HCV NS5B), remdesivir, molnupiravir | HCV, COVID-19
Microbiology: Virology - structure, replication and important viral infections